Viewing StudyNCT04224493

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 2:07 PM
Last Modification Date: 2024-10-26 @ 1:25 PM
Study NCT ID: NCT04224493
Status: RECRUITING
Last Update Posted: 2024-07-01
First Post: 2019-12-12
Brief Title: A Study to Assess the Efficacy Safety Pharmacodynamics and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With RelapsedRefractory Follicular Lymphoma
Sponsor: Epizyme Inc
Organization: Ipsen
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
RelapsedRefractory Follicular Lymphoma
Follicular Lymphoma
Refractory Follicular Lymphoma
Keywords:
Name View
Epizyme View
Tazverik View
Tazemetostat EPZ-6438 View
Lenalidomide View
Revlimid View
Rituximab View
Rituxan View
Follicular lymphoma View
EZH2 View